Addex Therapeutics (ADXN) Cash from Financing Activities (2022 - 2025)
Historic Cash from Financing Activities for Addex Therapeutics (ADXN) over the last 4 years, with Q2 2025 value amounting to -$118.4 billion.
- Addex Therapeutics' Cash from Financing Activities rose 3495.05% to -$118.4 billion in Q2 2025 from the same period last year, while for Jun 2025 it was -$8.0 billion, marking a year-over-year increase of 9987.08%. This contributed to the annual value of $119260.5 for FY2024, which is 9796.55% down from last year.
- According to the latest figures from Q2 2025, Addex Therapeutics' Cash from Financing Activities is -$118.4 billion, which was up 3495.05% from $109.0 billion recorded in Q1 2025.
- In the past 5 years, Addex Therapeutics' Cash from Financing Activities ranged from a high of $6130.2 billion in Q2 2023 and a low of -$6000.8 billion during Q4 2023
- Over the past 4 years, Addex Therapeutics' median Cash from Financing Activities value was -$176047.7 (recorded in 2022), while the average stood at -$6.1 billion.
- The largest annual percentage gain for Addex Therapeutics' Cash from Financing Activities in the last 5 years was 346783316935.01% (2023), contrasted with its biggest fall of 342275858073.99% (2023).
- Quarter analysis of 4 years shows Addex Therapeutics' Cash from Financing Activities stood at -$175321.9 in 2022, then tumbled by 3422758580.74% to -$6000.8 billion in 2023, then skyrocketed by 97.97% to -$121.7 billion in 2024, then rose by 2.77% to -$118.4 billion in 2025.
- Its last three reported values are -$118.4 billion in Q2 2025, $109.0 billion for Q1 2025, and -$121.7 billion during Q4 2024.